Gene therapy for solid tumors using adenoviral vectors comprising suicide genes and cytokine genes

ABSTRACT

The present invention provides a novel method of treating localized solid tumors and papillomas in an individual, as well as metastatic carcinomas. The method comprises delivering a suicide gene, by way of a recombinant adenoviral vector or other DNA transport system, into the tumor, papilloma or wart of an individual. Subsequently, a prodrug, such as the drug gaciclovir™, is administered to the individual. Additionally, the present invention provides a method for treating solid tumors, papillomas, warts and metastatic carcinomas, said method comprising introducing both a suicide gene and one or more cytokine genes into the tumor, papilloma or wart of an individual, and subsequently administering a prodrug to the individual. The methods of the present invention may be used to treat several different types of cancers and papillomas, including colon carcinoma, prostate cancer, breast cancer, lung cancer, melanoma, hepatoma, brain lymphoma and head and neck cancer.

This application is a 371 of PCT/US94/09784 and a continuation-in-partof Ser. No. 08/112,745, filed Aug. 26, 1993, now U.S. Pat. No.5,631,236.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates generally to the field of gene therapy.More particularly, the present invention relates to a novel gene therapymethod of treating solid tumors, papillomas and warts using anadenoviral vector, a combination of adenoviral vectors, other viralvectors, and non-viral DNA transporter systems.

2. Description of the Related Art

Direct introduction of therapeutic genes into malignant cells in vivocan provide an effective treatment of localized tumors. Several noveltreatment modalities have recently been attempted. For example, onetreatment involves the delivery of normal tumor suppressor genes and/orinhibitors of activated oncogenes into tumor cells. A second treatmentinvolves the enhancement of immunogeneity of tumor cells in vivo by theintroduction of cytokine genes. A third treatment involves theintroduction of genes that encode enzymes capable of conferring to thetumor cells sensitivity to chemotherapeutic agents. The herpes simplexvirus-thymidine kinase (HSV-TK) gene can specifically convert anucleoside analog (ganciclovir) into a toxic intermediate and causedeath in dividing cells. It has recently been reported by Culver et al.(Science 256:1550-1552, 1992) that after delivery of the HSV-TK gene byretroviral transduction, subsequent ganciclovir treatment effectivelycaused brain tumor regression in laboratory animals. An attractivefeature of this treatment modality for localized tumors is the so called"by-stander" effect. In the "by-stander" effect, the HSV-TK expressingtumor cells prevent the growth of adjacent non-transduced tumor cells inthe presence of ganciclovir. Thus, not every tumor cell has to expressHSV-TK for effective cancer treatment.

The HSV-TK retrovirus used by Culver et al., however, was limited by lowviral titer. Thus, effective treatment of brain tumors necessitated theinoculation into animals of virus-producing cells rather than the viralisolate itself. Additionally, in previous experiments with synergeneicrats treated with a retrovirus and ganciclovir, the tumors were necroticand were invaded by macrophages and lymphocytes. In Example 1, below,athymic mice were used and the tumor cells were destoyed withoutapparent involvement of the cellular immune response. The prior artremains deficient in the lack of an efficient gene therapy technique forthe treatment of solid tumors.

SUMMARY OF THE INVENTION

An object of the present invention is a novel method of gene therapy inhumans and animals.

An additional object of the present invention is a method of treatingcancer by introducing an adenoviral vector encoding a protein capable ofenzymatically converting a prodrug, i.e., a non-toxic compound into atoxic compound, and subsequently administering the prodrug.

A further object of the present invention is to provide a method forcombination gene therapy using an-adenoviral vector with a "suicidegene", a protein capable of converting a prodrug; co-administered with a"cytokine gene", such as the interleukin-2 gene; and subsequentlyadministering the prodrug.

Thus, in accomplishing the foregoing objects there is provided inaccordance with one aspect of the present invention a method of treatinga solid tumor, papilloma or warts in an animal or human, comprisingsteps of: introducing an adenoviral vector directly into solid tumor,that vector comprised of the following elements linked sequentially atappropriate distance for functional expression: a promoter, a 5' mRNAleader sequence, an initiation site, a nucleic acid cassette containingthe suicide gene sequence to be expressed, a 3' untranslated region; anda polyadenylation signal; and administering a prodrug to animal orhuman, wherein prodrug is converted in vivo in to a toxic compound.

Further, in accomplishing the foregoing objects, there is provided inaccordance with one aspect of the present invention a method of treatinga solid tumor, papilloma or wart in an animal or human, comprising stepsof: introducing an adenoviral vector directly into the solid tumor, thatvector comprised of the following elements linked sequentially atappropriate distance for functional expression: a promoter, a 5' mRNAleader sequence, an initiation site, a nucleic acid cassette containinga suicide gene, a 3' untranslated region, and a polyadenylation signal;and at the same time introducing a second adenoviral vector, that vectorcomprised of the following elements linked sequentially at appropriatedistance for functional expression: a promoter; a 5' mRNA leadersequence, an initiation site, a nucleic acid cassette containing acytokine gene, a 3' untranslated region, and a polyadenylation signal;and administering a prodrug to animal or human, wherein prodrug isconverted in vivo in to a toxic compound.

Other and further objects, features and advantages will be apparent fromthe following description of the presently preferred embodiments of theinvention which are given for the purpose of disclosure when taken inconjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a schematic representation of the construction ofrecombinant adenoviral vectors containing the herpes simplex virusthymidine kinase (HSV-TK) gene.

FIGS. 2(A-D) shows the efficient transduction of C6 glioma cells invitro using a recombinant adenoviral vector containing the bacterialβ-galactosidase gene (β-gal). Panel A: moi=O; Panel B: moi=125; Panel C:moi=500 and Panel D, moi=2,0000.

FIG. 3 shows HSV-TK enzymatic activity in C6 glioma cells aftertransduction with a recombinant adenoviral vector containing the HSV-TKgene.

FIG. 4 shows the susceptibility to ganciclovir toxicity of Ad/RSV-TKtransduced C6 glioma cells in vitro.

FIG. 5 shows the strategy for gene therapy of brain tumors usingrecombinant adenoviral vectors containing HSV-TK.

FIG. 6 shows a strategy for gene therapy of a generic solid tumor.

FIG. 7 shows experimental animals at 20 days post C6 Glioma cellinoculation into the brain, followed by stereotactic Ad/RSV-TKadministration. The left animal was treated with PBS and the rightanimal treated with ganciclovir.

FIG. 8 shows whole brain of mice as described in FIG. 7 after either PBStreatment (left) or ganciclovir treatment (right).

FIG. 9 shows a schematic of the effect of ganciclovir treatment andHSV-TK⁺ breast tumor (MOD) regression.

FIG. 10 shows the effect of ganciclovir treatment on HSV-TK⁺ breasttumor (MOD) size.

FIG. 11 shows a schematic of the bystander effect when parental breasttumor (MOD) cells and tumor cells containing the HSV-TK gene were mixedand injected subcutaneously into mice.

FIG. 12 shows the effect of PBS or ganciclovir on tumor size when micehad been treated with either 100% parental tumor cells, 100% HSV-TKcontaining tumor cells, 90% parental/10% HSV-TK tumor cells or 50%parental/50% HSV-TK breast tumor (MOD) cells.

FIG. 13 shows the effect of ganciclovir dose on brain tumor size afteradenovirus-mediated gene therapy. Small residual tumors were noted insome brains of ADV/tk treated rats that received less than 80 mg/kgganciclovir. Error bars=S.D. Treatments, mean tumor areas ±S.D., andsample sizes are: A ADV-tk+PBS, 36.89±6.73 mm² (n=3); B ADV-βgal+150mg/kg ganciclovir, 28.75±0.55 mm² (n=4); C ADV-tk+150 mg/kg ganciclovir,-0 mm² (n=2); D ADV-tk+100 mg/kg ganciclovir, 0 mm² (n=4); E ADV-tk+80mg/kg ganciclovir, 0 mm² (n=2); F ADV-tk+50 mg/kg ganciclovir, 0.25±0.29mm² (n=4); G ADV-tk+20 mg/kg ganciclovir, 1.79±3.52 mm² (n=4); HADV-tk+10 mg/kg ganciclovir, 0.01±0.004 mm² (n=4).

FIG. 14 illustrates the results of a survival study of animals treatedwith either ADV-βgal or ADV-tk and then 50 mg/kg of ganciclovir twicedaily for 6 days. A: those animals treated with ADV-βgal plusganciclovir died within 22 days (--; n=7); B: animals in first grouptreated with ADV-tk plus ganciclovir remain alive after 120 days exceptfor one animal that died after 98 days from an unknown cause (. . . ;n=4); C: animals in the second group treated with ADV-tk plusganciclovir remain alive after 80 days (--------; n=5).

FIG. 15 shows ADV/RSV-TK transduction of HLaC-79 human squamous cancercells in vitro followed by treatment of either GCV 10 ug/ml (solid bars)or PBS (striped bars). Call survival was assessed 68 hours aftertransduction in both GCV treatment and PBS control groups. Treatmentwith GCV resulted in 85-90x cancer cell killing at very low M.O.I.Nontransduced controls (M.O.1=0) and PBS controls demonstrated notoxicity up to an M.O.I. of 25.

FIG. 16 presents the mean percent necrosis of squamous cell tumors invivo for each experimental group. A substantial cytotoxic effect (41%necrosis) was seen after adenovirus transduction and ganciclovirtreatment (TK+C+) compared to controls (0-2.2% necrosis). Statisticalsignificance per t-Test analysis: p<0.001.

FIG. 17 shows tumor index values (dots) depicting the overall clinicalresponse for each animal in the experimental groups. Data at or belowthe horizontal line (tumor index of 30 or less) indicate near totaltumor regression. Bars show median values for each group. Dramaticclinical response was seen in the complete treatment animals (TK+G+)compared to each control group (p<0.001-0.02 per Mann-Whitney analysis).

FIG. 18 shows the functional characterization of the recombinantadenoviral vectors: GCV susceptibility of ADV/RSV-tk transduced MCA-26colon tumor cell lines. MCA-26' cells were transduced with ADV/RSV-tk atvarious multiplicities of infection, followed by either PBS or 10 ug/mlGCV treatment 12 hours later. After 3 days, the viable cells weredetermined by trypan blue staining.

FIG. 19 shows the results of a mouse IL2 bioassay of conditioned mediafrom B16 cells transduced with ADV/RSV-mIL2. The conditioned media wereadded to a mouse T-cell line CTLL-2 and cultured for 20 hrs. ³H:thymidine was added for another 4 hrs and the cells were collectedusing a PHD cell harvester. Incorporated ³ H-thymidine was determined byliquid scintillation counting and mean cpm of triplicate cultures isshown.

FIG. 20 demonstrates residual tumor sizes in animals after various genetherapy treatments. Maximal cross sectional areas of the tumors weremeasured by computerized morphometric analysis. The cumulative number ofanimals in the 5 treatment groups from two separate experiments were 14(βgal); 8 (mIL2); 7 (β-gal+mIL2); 12 (tk) and 10 (tk+mIL2). The errorbars represent standard deviations in each treatment group.

FIG. 21 shows systemic anti-tumoral immunity against parental tumor cellchallenges at distal sites. Tumor cells were inoculated subcutaneouslyin animals of all five treatment groups. 1×10⁵ MCA-26 cells wereinjected into the right flank of the animals one day after completion ofGCV treatment, and 2×10⁶ M0D breast tumor cells were injected to theleft flank of the animals. These were tumorigenic doses that wouldresult in visible tumors of similar sizes in normal BALB/c mice after 7days. Presence of subcutaneous tumors in the challenged animals wasnoted visually after one week. The number of animals challenged withMCA-26 was 6 in each group and those challenged with M0D ranged between2-4 per group.

FIG. 22 shows cytotoxic T lymphocyte response in animals after variousgene therapy treatments. Splenocytes were isolated from animals invarious treatment groups at 3 days after the completion of GCVadministration. 6×10⁶ splenocytes were stimulated in vitro byco-cultivation with 5×10⁵ irradiated MCA-26 cells for 5 days before the⁵¹ Cr release assays were performed. Percent MCA-26 target cell daysbefore the ⁵¹ Cr release was plotted versus various effector/target cellratios. Data represent mean specific ⁵¹ Cr release from triplicatecultures.

FIG. 23 shows the in vitro blocking of CTL response using monoclonalantibodies against either CD4 or CD8. Splenocytes from animals treatedwith ADV/RSV-tk+ADV/RSV-mIL2 were stimulated in vitro as in the legendof FIG. 5A, and the effector cells were then incubated with variousconcentrations of purified, sodium azide-free antibodies (GKI.5.,monoclonal antibody to CD4 or 2.43, monoclonal antibody to CD8_(a),Pharmingen) at -37° C. for 30 minutes. The ⁵¹ Cr release assay wasperformed at an effector to target cell ratio of 50/1.

The drawings are not necessarily to scale. Certain features of theinvention may be exaggerated in scale or shown in schematic form in theinterest of clarity and conciseness.

DETAILED DESCRIPTION OF THE INVENTION

It will be readily apparent to one skilled in the art that varioussubstitutions and modifications may be made to the invention disclosedherein without departing from the scope and spirit of the invention.

The term "vector " as used herein refers to a construction comprised ofgenetic material designed to direct transformation of a targeted cell. Avector contains multiple genetic elements positionally and sequentiallyoriented, i.e., operatively linked with other necessary elements suchthat the nucleic acid in a nucleic acid cassette can be transcribed andwhen necessary, translated in the transfected cells. In the presentinvention, the preferred vector comprises the following elementsoperatively linked for functional expression: a promoter, a 5' mRNAleader sequence, an initiation site, a nucleic acid cassette containingthe sequence to be expressed, a 3' untranslated region, and apolyadenylation signal.

The term "stable transformation" as used herein refers to transformationin which the introduced therapeutic nucleic acid sequence (suicide gene)is, or the introduced therapeutic nucleic acid sequence and the cytokinesequence are, incorporated into the chromosomes of the whole cell. Thisleads to apparent stable change or transformation of a givencharacteristic of a cell.

The term "transformed" as used herein refers to a process for making orintroducing a stable change in the characteristics (express phenotype)of a cell by the mechanism of gene transfer whereby DNA or RNA isintroduced into a cell in a form where it expresses a specific geneproduct or alters an expression or affects endogenous gene products. Thevector can be introduced into the cell by a variety of methods includingmicroinjection, CaPO₄ precipitation, lipofection (liposome fusion), useof a gene gun and DNA vector transporter.

Recombinant adenoviruses containing the HSV-TK gene can be driven byvarious promoters including that of the cytomegalovirus, Rouse sarcomavirus LTR, murine leukemia virus LTR, simian virus 40 early and late,and endogenous HSV-TK genes. The recombinant adenoviruses are used todeliver efficiently the HSV-TK gene to tumors. Adenoviral vectors haveseveral biological characteristics that make them more effective thanretrovirus for somatic gene therapy of brain tumors. Adenoviral vectorshave a broad host and cell range; multiple infection of host cells canproduce high levels of gene expression; infection is episomal so thatthere is little possibility of insertional mutation of host genes; andhigh viral titers of up to 1×10¹¹ particles/ml can be produced.

A wide variety of cancer, papillomas and warts can be treated by thesame therapeutic strategy. Representative examples include coloncarcinoma, prostate cancer, breast cancer, lung cancer, skin cancer,liver cancer, bone cancer, ovary cancer, pancreas cancer, brain cancer,head and neck cancer, lymphoma and other solid tumors. Representativeexamples of papillomas include squamous cell papilloma, choroid plexuspapilloma and laryngeal papilloma. Representative examples of wartconditions include genital warts, plantar warts, epidermodysplasiaverruciformis and malignant warts.

The term "nucleic acid cassette" as used herein refers to the geneticmaterial of interest which can express a protein, or a peptide, or RNA.The nucleic acid cassette is operatively linked i.e., positionally andsequentially oriented in a vector, with other necessary elements suchthat the nucleic acid in the cassette can be transcribed and, whennecessary, translated.

The present invention provides a method of treating a localized solidtumor, papilloma or wart in an animal or human, comprising steps of:introducing an adenoviral vector directly into said tumor or papilloma,comprised of the following elements linked sequentially at appropriatedistance for functional expression: a promoter, a 5' mRNA leadersequence, an initiation site, a nucleic acid cassette containing thesequence to be expressed, a 3' untranslated region, and apolyadenylation signal; and administering a prodrug to animal or human,wherein prodrug is converted in vivo into a toxic compound.

Another aspect of the present invention provides a method of treatingsolid tumors, papillomas or warts in an animal or human, comprisingsteps of: introducing an adenoviral vector directly into solid tumor,that vector comprised of the following elements linked sequentially atappropriate distance for functional expression: a promoter, a 5' mRNAleader sequence, an initiation site, a nucleic acid cassette containinga suicide gene, a 3' untranslated region, and a polyadenylation signal;and at the same time introducing a second adenoviral vector, that vectorcomprised of the following elements linked sequentially at appropriatedistance for functional expression: a promoter, a 5' mRNA leadersequence, an initiation site, a nucleic acid cassette containing acytokine gene, a 3' untranslated region, and a polyadenylation signal;and administering a prodrug to animal or human, wherein prodrug isconverted in vivo into a toxic compound.

In addition to adenoviral vectors, other delivery systems may be used,either viral or non-viral. A targeted system for non-viral forms of DNAor RNA requires four components: 1) the DNA or RNA or interest; 2) amoiety that recognizes and binds to a cell surface receptor or antigen;3) a DNA binding moiety; and 4) a lytic moiety that enables thetransport of the complex from the cell surface to the cytoplasm.Examples of such non-viral transfer systems may be found in Smith andWoo, U.S. Ser. No. 07/855,389, filed Mar. 20, 1992. Further, liposomesand cationic lipids can be used to deliver the therapeutic genecombinations to achieve the same effect. Potential viral vectors includeexpression vectors derived from viruses such as vaccinia virus, herpesvirus, and bovine papilloma virus. In addition, episomal vectors may beemployed. Other DNA vectors and transporter systems are known in theart. Currently, the preferred embodiment envisions the use of anadenovirus system.

In the method of the present invention, the therapeutic nucleic acidsequence or "suicide gene" is a nucleic acid coding for a product,wherein the product causes cell death by itself or in the presence ofother compounds. A representative example of such a therapeutic nucleicacid (suicide gene) is one which codes for thymidine kinase of herpessimplex virus. Additional examples are thymidine kinase of varicellazoster virus and the bacterial gene cytosine deaminase which can convert5-fluorocytosine to the highly toxic compound 5-fluorouracil.

As used herein "prodrug" means any compound useful in the methods of thepresent invention that can be converted to a toxic product, i.e. toxicto tumor cells. The prodrug is converted to a toxic product by the geneproduct of the therapeutic nucleic acid sequence (suicide gene) in thevector useful in the method of the present invention. Representativeexamples of such a prodrug is ganciclovir which is converted in vivo toa toxic compound by HSV-thymidine kinase. The ganciclovir derivativesubsequently is toxic to tumor cells. Other representative examples ofprodrugs include acyclovir, FIAU[1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-5-iodouracil],6-methoxypurine arabinoside for VZV-TK, and 5-fluorocytosine forcytosine deambinase.

Ganciclovir may be administered readily by a person having ordinaryskill in this art. A person with ordinary skill would readily be able todetermine the most appropriate dose and route for the administration ofganciclovir. Preferably, ganciclovir is administered in a dose of fromabout 1-20 mg/day/kg body weight. Preferably, acyclovir is administeredin a dose of from about 1-100 mg/day/kg body weight and FIAU isadministered in a dose of from about 1-50 mg/day/kg body weight.

In another method of the present invention, an adenovirus containing acytokine gene sequence can be driven by various promoters including RousSarcoma Virus-Long Terminal Repeat, cytomegalovirus promoter, murineleukemia virus LTR, simian virus 40 early and late promoters, and herpessimplex virus thymidine kinase. This cytokine gene-containing adenoviruscan then be co-administered with the suicide gene-containing adenovirus,to effect a "combination gene therapy."

As used herein, "cytokine gene" means a gene encoding any one of thesoluble subtances produced by lymphoid or non-lymphoid cellscharacterized by their ability to respond to anitgen invasion. Thisincludes the inferons and factors involved in the stimulation of helperand cytolytic T-lymphocytes to mount an effective anti-tumoral response,as well as macrophages and monocytes to assist in the activation ofB-lymphocytes to antibody-producing cells. Cytokine genes includeinterleukin-1, interleukin-2, interleukin-4, interleukin-6,interleukin-7, interleukin-10, interleukin-12, interferon-α,interferon-β, interferon-δ, tumor necrosis factor α and β,granulocyte-macrophage colony stimulating factor (GM-CSF) andgranulocyte colony stimulating factor (G-CSF).

Abbreiviations used herein include: ADV/RSV-TK, a recombinant vectorcontaining the thymidine kinase gene driven by the Rous Sarcoma Viruslong terminal repeat; ADV/RSV-β-gal, the same vector as above butcontaining the gene for β-galactosidase; TK, Herpes simplex virusthymidine kinase gene; GCV, ganciclovir; PBS, phosphobuffered saline.

The following examples are offered by way of illustration and are notintended to limit the invention in any manner.

EXAMPLE 1

Gene therapy for brain tumors: Regression of experimental gliomas byadenovirus-mediated gene transfer in vivo.

Construction of the adenoviral vector.

The construction of recombinant adenoviral vectors containing the herpessimplex virus-thymidine kinase (HSV-TK) gene (Summers, W. C., et al. atPNAS 78(3), pp. 1441-1445 (1981)) is shown in FIG. 1. Three differentvectors were constructed, each with a different promoter inserted 5' tothe coding sequence and polyadenylation signal of the HSV-TK gene: (1)the long terminal repeat sequence of the Rous Sarcoma Virus (Ad/RSV-TK);(2) the early gene promoter of the cytomegalovirus (Ad/CMV-TK); and (3)the thymidine kinase gene promoter of herpes simplex virus (Ad/HSV-TK).

Transduction of C6 Glioma cell.

Transduction of C6 glioma cells in vitro was accomplished using arecombinant adenoviral vector containing the bacterial B-galactosidasegene. 5×10⁵ C6 cells were plated on 1.5 cm diameter wells and transducedwith AdV/RSV-B-gal at various viral doses and stained with X-gal twodays later. Panel A illustrates the results using an moi of O. Panel Bshows the results using an moi of 125. Panel C illustrates the resultsusing an moi of 500 and Panel D shows the results when an moi of 2,000was used.

Transduction of C6 cells usinz the HSV-TK gene.

Transduction of C6 glioma cells was also accomplished using arecombinant adenoviral vector containing the HSV-TK gene (Ad/RSV-TK).5×10⁵ C6 cells were plated on 1.5 cm diameter wells and transduced withthe viral vector at different doses as indicated. Cells were harvestedtwo days later and protein extracts prepared. The HSV-TK enzymaticactivity was d e termined by phosphorylation of ³ H-acyclovir asdescribed in James, et al., J. Biol. Chem., 253 (24):8721-8727 (1978).

As can be seen from FIG. 3, HSV-TK activity was highest in C6 cellsafter transduction with AD/RSV-TK having an m.o.i. of 1000 and 2000,respectively.

Ganciclovir susceptibility of HSV-TK⁺ C6 cells.

The susceptibility to ganciclovir toxicity of Ad/RSV-TK transduced C6glioma cells is shown in FIG. 4. Duplicate plates of viral transducedcells in FIG. 3 were subjected to ganciclovir treatment at 2 ug/ml andthe number of survival cells was counted at 72 hours.

FIG. 4 illustrates the effect of ganciclovir in C6 cells aftertransduction with AD/RSV-TK. FIG. 4 shows that an m.o.i. of 250 produceda cell kill of 62.5%; and m.o.i. of 500 resulted in a cell kill of 75%.Most dramatically, an m.o.i. of 1000 resulted in a cell kill ofapproximately 95%.

Gene therapy strategy.

The strategy for gene therapy of brain cancer using recombinantadenoviral vectors containing HSV-TK is shown in FIGS. 5 and 6. In FIG.5, C6 glioma cells were injected stereotactically into nude mouse brainwith a little charcoal to mark the site of injection. About 1 weeklater, Ad/RSV-TK was injected into the tumor stereotactically. The micewere then divided into 2 groups, one treated with ganciclovir for 6 daysand the other with phosphate-buffered saline (PBS). The animals werethen kept without further treatment until tumors developed, i.e., aboutone to two weeks.

FIG. 6 shows intra-organ injections of tumor cells into mice. After 4-8days, the mice were divided into two groups. In one group AD/β-gal wasinjected into the tumor and in the other group AD/HSV-TK was injectedinto the tumor. After about 1-2 weeks, half the mice in each group weretreated with PBS and the other half were treated with ganciclovir. Onlythe mice treated with ganciclovir and AD/HSV-TK showed tumor regression.

Effect of Ad/RSV-TK injection and Ganciclovir on brain tumors.

Experimental animals were inoculated with 10⁴ C6 glioma cells bystereotactic injection into the brain. After 4-8 days, 3×10⁸ particlesof recombinant adenoviral vector containing the HSV-TK (Ad/RSV-TK) genewere stereotactically injected into the same site. Twelve hours later,the animals were treated daily either by intraperitoneal administrationwith buffer (PBS) or Ganciclovir (GCV:125 mg/kg) for 6 consecutive days.The animals were kept without further treatment until the 20th day fromthe day of tumor cell inoculation and the appearance of brain tumors forindividual animals was recorded.

FIG. 7 shows experimental animals at 20 days post C6 glioma cellinoculation into the brain followed by stereotactic Ad/RSV-TKadministration. A representative PBS-treated animal with obvious braintumor is shown on the left panel of FIG. 7 and a representativeGCV-treated mouse without obvious brain tumor is shown on the rightpanel of FIG. 7.

Gross anatomy of mouse brains with and without tumor.

FIG. 8 shows whole brains of mice after either PBS treatment (left) organciclovir treatment (right) as described in Example 6. The brains wereobtained from experimental animals at 20 days after tumor cellinoculation as described above. The tumor mass in PBS treated mice wasdissected from the brain and placed on top of the organ. Furthermore,because the C6 glioma cells were originally injected into mouse brainwith a little charcoal, the ganciclovir treated mouse brain has a specof charcoal which demonstrates the site of tumor cell injection.

                  TABLE I                                                         ______________________________________                                        Brain Tumor Treatment with an Adenoviral Vector                               having the HSV-TK Gene                                                        TREATMENT              PBS    GGV                                             ______________________________________                                        Number of Treated Animals                                                                            4      4                                               Number of Animals with Brain Tumor                                                                   4      1                                               ______________________________________                                    

EXAMPLE 2

Effect of ganciclovir on a breast cancer cell line.

Treatment of localized breast cancer tumors in mice.

The "by-stander" effect in solid tumors was examined using a breastcancer cell line (MOD) derived from BALB/c mouse. This cell line easilyforms localized tumors by subcutaneous injection of tumor cells intocongenic recipients. Thus, this cell line can be used as a model forgene therapy for breast cancer.

FIG. 9 is a schematic of the effect of ganciclovir treatment and HSV-TK⁺tumor regression. FIG. 9 shows that, in one case, the parental tumorcells were injected subcutaneously in mice. The mice were divided intotwo groups. One group was treated with PBS; the other group was treatedwith GCV for 5 days. Two weeks later, the animals were sacrificed. FIG.9 also shows that another group of mice were injected with tumor cellsinto which the HSV-TK gene was inserted in vitro (HSV-TK⁺).Subsequently, the mice were treated with either PBS or GCV as describedabove.

FIG. 10 shows the effect of ganciclovir treatment on tumor size. The toppanel shows that there was little significant difference betweentreatment with PBS or GCV in mice injected with the parental cellsalone. The bottom panel of FIG. 10 shows that ganciclovir treatmentsignificantly reduced tumor size when the HSV-TK gene had been insertedinto the tumor cells prior to injection into the mice.

FIG. 11 shows a schematic of the bystander effect. In the schematic ofFIG. 11, parental tumor cells and tumor cell containing the HSV-TK genewere mixed and injected subcutaneously into mice. The mice were thentreated with either PBS or GCV.

Results

HSV-TK gene transformed MOD cells in vitro exhibited greatly enhancedsensitivity to the toxic effects of ganciclovir over the parental tumorcells. When tested in vivo, not only the growth of HSV-TK genetransformed MOD cells were inhibited by intraperitoneal administrationof ganciclovir but the sold tumors also regressed in mice. Regression,however, was not observed with tumors derived purely from the parentaltumor cells. More importantly, a strong "by-stander" effect in thebreast tumor cells in vivo was also observed. When animals wereco-injected with the HSV-TK expressing MOD cells and the parental tumorcells, as few as 10% of HSV-TK expressing cells was sufficient toinhibit overall tumor growth in the animals after ganciclovir treatment(FIG. 12). In this set of animals however, the tumors recurred after30-45 days. On the other hand, animals inoculated with 90% or 50% TK⁺cells remained tumor free during this period.

Cell-type specificity of HSV-TK gene expression after recombinantadenoviral vector administration in a particular solid tumor, papillomaor wart can also be achieved with the use of tissue-specific promotersto direct the transcription of the HSV-TK gene. Some examples of thevarious tissue specific promoters are shown in Table II.

                  TABLE II                                                        ______________________________________                                        TUMOR         PROMOTERS                                                       ______________________________________                                        liver         albumin, alpha-fetoprotein, α.sub.1 -                                   antitrypsin, transferrin transthyretin                          colon         carbonic anhydrase I,                                                         carcinoembrogen's antigen                                       ovary, placenta                                                                             estrogen, aromatase cytochrome P450,                                          cholesterol side chain cleavage P450,                                         17 alpha-hydroxylase P450                                       prostate      prostate specific antigen, gp91-phox                                          gene, prostate-specific kallikrein                                            (hKLK2)                                                         breast, G.I.  erb-B2, erb-B3, β-casein, β-lacto-                                  globulin, WAB (whey acidic protein)                             lung          surfactant protein C Uroglobin (cc-10,                                        Cllacell 10 kd protein)                                         skin          K-14-keratin, human keratin 1 or 6,                                           loicrin                                                         brain         glial fibrillary acidic protein,                                              mature astrocyte specific protein,                                            myelin, tyrosine hydroxylase                                    pancreas      villin, glucagon, Insulin                                                     Islet amyloid polypeptide (amylin)                              thyroid       thyroglobulin, calcitonin                                       bone          Alpha 1 (I) collagen, osteocalcin,                                            bone sialoglycoprotein                                          kidney        renin, liver/bone/kidney alkaline                                             phosphatase, erythropoietin (epo)                               ______________________________________                                    

EXAMPLE 3

Adenovirus-mediated Gene Therapy of experimental gliomas.

The efficacy of adenoviral-mediated gene therapy to treat brain tumorswas shown in a syngeneic glioma model. Tumor cells were transduced insitu with a replication-defective adenovirus (ADV) carrying the herpessimplex virus thymidine kinase gene (HSV-tk) controlled by the Roussarcoma virus promoter. Expression of the HSV-tk gene enables thetransduced cell to convert the drug ganciclovir to a form that iscytotoxic to dividing cells. Tumors were generated in Fischer 344 ratsby stereotaxic implantation of 9L gliosarcoma cells into the caudatenucleus. Eight days later, the tumors were injected either with the ADVcarrying the HSV-tk gene (ADV-tk) or a control ADV vector containing theβ-galactosidase gene (ADV-βgal) and the rats were treated with eitherganciclovir or with saline. Tumor size was measured 20 days afterimplantation of 9L cells or at death. Rats treated with ADV-βgal andganciclovir or with ADV-tk and saline had large tumors. No tumors weredetected in animals treated with ADV-tk and with ganciclovir at doses≧80 mg/kg. An infiltrate of macrophages and lymphocytes at the injectionsite in animals treated with ADV-tk and ganciclovir indicated an activelocal immune reaction. In survival studies, all animals treated withADV-tk and ganciclovir have remained alive longer than 80 and up to 120days after tumor induction, whereas all untreated animals died by 22days. These results demonstrate that adenovirus-mediated transfer ofHSV-tk to glioma cells in vivo confers sensitivity to ganciclovir, andrepresents a method of treatment of brain tumors.

Adenoviral Constructs.

ADV-tk vector was prepared by inserting HSV-tk into the plasmid whichcontained the Rous sarcoma virus long-terminal-repeat promoter (RSV-LTR)to generate pADL.1/RSV-tk (Chen et al., 1994). Recombinant adenoviruswas produced by co-transfecting 293 cells with pADL.1/RSV-tk and aplasmid, pJM17, containing the adenovirus genome. The 293 cells aretransformed human kidney cells the E1 region of the adenovirus genome.When 293 cells were co-transfected with pADL.1/RSV-tk and pJM17,replication-defective adenovirus was by homologous recombination (Grahamand Prevec, 1991). Virus titer was determined by optical absorbance at260 nm. A replication-deficient adenovirus vector carrying the E. coliβ-galactosidase gene under control of the RSV-LTR (ADV-βgal) was used asa control vector.

Experimental Tumor Generation.

In vivo the 9L tumor cells exhibit morphology described as mixedglioblastoma and sarcoma, or gliosarcoma (Barker et al., 1973;Weizaecker et al., 1981). The 9L glioma cells were maintained inDulbecco's modified Eagle medium (DMEM) supplemented with 10% fetalbovine serum, penicillin (100 U/ml), and streptomycin (100 μg/ml) in 5%CO₂ at 37° C. The tumor cells were harvested for injection by treatingthe cells at 37° C. with 0.25% trypsin in 1.0 mM ethylenediaminetetra-acetic acid for 5 minutes. The cells were collected in DMEM,washed, and resuspended in Hanks' balanced salt solution (HBSS) at aconcentration of 2.0×10¹³ cells/μl. Cells were counted before and afterconcentrating and prior to injection with a hemacytometer. Following theimplantation procedure the viability of the cell preparation wasassessed by trypan blue exclusion analysis.

Adult female Fischer 344 rats (155-175 grams) were used as host animals.Rats were anesthetized with an intramuscular injection (0.6 ml/kg) of ananesthetic consisting of ketamine (42.8 mg/ml), xylazine (8.6 mg/ml),and acepromazine (1.4 mg/ml) and were placed into a stereotaxic frame. Amid-line incision was made in the scalp, and a burr hole was made with a0.9 mm drill bit 1.8 mm to the right and 2.5 mm anterior to the bregma.Using a 10 μl syringe fitted with a 26 gauge needle and connected to themanipulating arm of the stereotactic frame, 1×10⁴ 9L glioma cellssuspended in 5 μl of HBSS were injected in 0.2 μl increments over 5minutes into the right caudate nucleus at a depth of 4.5 mm from thedura. The needle was left in place for 3 minutes and then withdrawnslowly over another 3 minutes. The burr hole was closed with bone waxand the scalp wound was closed with clips. Tumors were 1.65±0.094 mm²(n=4) in diameter 9 days after tumor cell injection and, if leftuntreated, killed the hosts at a mean time of 20 days afterimplantation.

Adenoviral Transduction of Experimental Tumors.

Eight days after 9L tumor cell injection either ADV-tk or ADV-βgal wasinjected into the tumors using the same coordinates that were used fortumor implantation. Viral particles (1.2×10⁹) in 6 μl of 10 mM Tris-HCl,pH 7.4, 10% glycerol and 1 mM MgCl₂ were injected at 6 sites within thetumor bed. Starting at a depth of 5.5 mm below the dural surface, 1 μlof virus was injected and the needle raised 0.5 mm where -another 1 μlwas injected. This was repeated until a total of six 1 μl injectionswere made through the core of the tumor. Virus was injected over 5minutes at each position and then the needle was withdrawn slowly over 5minutes. Carbon particles (<30 μm) were placed on the shaft of theinjection needle to mark the injection site. The wound was closed withclips.

Ganciclovir Treatment of Experimental Tumors.

To demonstrate the effectiveness of ADV-tk and ganciclovir treatment onexperimental 9L tumors, 3 treatment groups were established: 1) ADV-tkplus 100 mg/kg ganciclovir (n=6); 2) ADV-βgal plus 100 mg/kg ganciclovir(n=4); 3) ADV-tk plus saline (n=7). Treatment began 12 hours after viralinjection. The animals received intraperitoneal injections ofganciclovir or of normal saline twice a day for 6 consecutive days.Twenty days after tumor cell injection or at death, the animals wereperfused with fixative, the brains sectioned and stained, and the tumorsize morphometrically determined.

The effect of ganciclovir dosage on the effectiveness of ADV-tktreatment was determined by establishing 7 experimental groups (n=4 foreach group) that were implanted with 9L cells, treated with 1.2×10⁹ADV-tk and then treated with ganciclovir at doses of 0, 10, 20, 50, 80,100 and 150 mg/kg twice daily for 6 days. Twenty days after tumorinduction the animals were perfused with fixative, the brains sectionedand stained, and the tumor size measured.

To show the effect of ADV-tk and ganciclovir treatment on long-termsurvival, 17 tumor-bearing animals were treated with ADV-tk andganciclovir (50 mg/kg) and 7 animals were treated with ADV-βgal andganciclovir (50 mg/kg). The animals were monitored daily and, if theyexhibited signs of morbidity or if they died, their brains were removedfor histological analysis.

Histological Analysis.

Animals were anesthetized and fixed by cardiac perfusion with 100 ml of10 mM phosphate buffered saline, pH 7.4 (PBS) containing heparin (10units/ml) followed by 200 ml of 4% paraformaldehyde in PBS. Brains wereremoved, placed in 4% paraformaldehyde in PBS for 24 hours, thencryoprotected in 21% sucrose in PBS for 24-48 hours at 40° C., mountedin OCT, frozen and sectioned on a cryostat. Sections were stained withhematoxylin and eosin or prepared for immunocytochemical analysis, Themaximal tumor cross-sectional area was measured using Bioscan Optimassoftware. Mean tumor values were compared using ANOVA statisticalanalysis. Immunocytochemical staining was performed using ED1anti-macrophage antibody (Dijkstra et al., 1985; Polman et al., 1986)diluted 1 to 500 on 40 μm sections.

Results

Effect of ADV Gene Therapy on Experimental Gliomas.

When the tumors were treated with ADV-βgal and ganciclovir (100 mg/kg)or with ADV-tk and saline large tumors were present in all brains 20days after tumor cell injection. The tumors were characterized byhypercellularity, nuclear pleomorphism, and mitoses without inflammatorycell infiltration. The tumors were generally well circumscribed andcaused compression of adjacent brain tissue. However, focalperi-vascular glioma infiltration into adjacent brain was seen. Incontrast, no tumor cells were seen in the brains of animals thatreceived ADV-tk and ganciclovir (100 mg/kg) treatment. Instead,macrophages, lymphocytes, neutrophils, necrosis and hemorrhage wereapparent in the tumor injection area. Although the ipsilateralintraventricular ependymal cell lining appeared damaged in specimens, nonecrosis, loss of neurons, demyelination, or inflammatory response wasobserved beyond the tumors or injection sites.

Dose-Response Effects of Ganciclovir Treatment.

Morphometric analysis of tumor size in animals treated with differentdoses of ganciclovir showed that even at low (10 mg/kg) doses ofganciclovir the ADV-tk plus ganciclovir treatments had significanteffects (P<0.005) on tumor size (FIG. 13). Large tumors were present inanimals treated with ADV-tk and saline and in animals treated withADV-βgal and ganciclovir whereas animals that were treated with ADV-tkand ganciclovir at doses of 80 to 150 mg/kg had no residual tumors.Animals treated with ganciclovir at doses of less than 80 mg/kg hadsmall residual tumors. A significant reduction (P<0.005) in tumor sizewas present in animals treated with ADV-βgal and 150 mg/kg ganciclovircompared to animals treated with ADV-tk and saline. This suggests thatganciclovir itself may exhibit cytotoxicity or inhibitory effects ontumor growth independent of thymidine kinase activity.

Survival Studies.

Long-term survival of animals treated with ADV-βgal or ADV-tk and 50mg/kg ganciclovir was measured in two experimental groups and in onecontrol group (FIG. 14). All control animals (n=5) that were treatedwith ADV-βgal and ganciclovir died within days after tumor injection andhad large intracranial tumors upon necropsy. Three of the four animalsin the first experimental group that was treated with ADV-tk andganciclovir (50 mg/kg) survived more than 120 days. One animal died at98 days. No tumor was present in the brain of this animal and no othercause of death was apparent at necropsy. The second experimental groupconsisted of five animals, all treated with ADV-tk and ganciclovir (50mg/kg). All of these animals have now survived for 80 days.

These experiments demonstrate that the transduction of experimentalgliomas using a recombinant adenoviral vector carrying HSV-tk conferssensitivity to the cytotoxic drug ganciclovir. Adenoviral vectors infectboth dividing and non-dividing cells, and multiple virions can infect acell, which increases the number of copies of recombinant genesexpressed per cell. In this study, no tumors were present in animalstreated with ADV-tk and ganciclovir at doses of 80, 100 and 150 mg/kg at20 days after tumor injection treatment whereas large tumors werepresent in control animals treated with ADV-tk and saline or ADV-βgaland ganciclovir. At ganciclovir doses of 50 mg/kg and less smallresidual tumors were observed in some animals at 20 days after 9L cellinjection. Despite the presence of residual tumors in animals treatedwith ADV-tk and 50 mg/kg ganciclovir who were killed for histologicalstudy at 20 days after implantation, in survival experiments animalstreated using the same protocol have survived as long as 120 days.Because of the rapid in vivo growth of implanted 9L gliosarcoma cells itis doubtful that any residual tumor cells exist in the long-termsurvivors, or if they do exist their biological behavior must bemodified.

EXAMPLE 4

Adenovirus-mediated gene therapy for human head and neck squamous cellcancer in a nude mouse model.

Adenovirus-mediated transfer of the herpes thymidine kinase genefollowed by ganciclovir administration was used to treat human head andneck squamous cell cancer implanted into the floor of the mouth of nudemice. Tumors were generated by transcutaneous needle injection of 6×10⁶cancer cells, and after 14 days, 10¹⁰ particles of a replicationdefective recombinant adenovirus containing the herpes simplex virusthymidine kinase gene (ADV/RSV.TK) were injected directly into thetumors. The mice were subsequently treated with GCV for 6 consecutivedays and then sacrificed at 21 days post tumor implantation. Clinicalresponse to the treatment was assessed by computer. Imaged morphometricanalysis of cross sectional area of non-necrotic tumor andmitotic-activity with the calculation of a tumor index. The median tumorindex value of the complete treatment group was 280 to 2400 fold smallerthan controls which did not receive the therapeutic gene(p<0.001-0.016), and three-quarters of the treatment group had tumorindex values that were indicative of near total tumor regression. Theseresults demonstrate that clinically effective in vivo treatment of humansquamous cell cancer was achieved using adenovirus-mediated genetherapy.

Adenoviral Constructs.

ADV-tk vector was prepared by inserting HSV-tk into the plasmid whichcontained the Rous sarcoma virus long-terminal-repeat promoter (RSV-LTR)to generate pADL.1/RSV-tk (Chen et al., 1994). Recombinant adenoviruswas produced by co-transfecting 293 cells with pADL.1/RSV-tk and aplasmid, pJM17, containing the adenovirus genome. The 293 cells aretransformed human kidney cells the E1 region of the adenovirus genome.When 293 cells were co-transfected with pADL.1/RSV-tk and pJM17,replication-defective adenovirus was by homologous recombination (Grahamand Prevec, 1991). Virus titer was determined by optical absorbance at260 nm. A replication-deficient adenovirus vector carrying the E. coliβ-galactosidase gene under control of the RSV-LTR (ADV-βgal) was used asa control vector.

In vitro experiments.

5×10⁵ HLAC-79 cells were plated on 1.5 cm diameter tissue culture platesin Eagle's MEM media containing 10% fetal calf serum with essentialamino acids and vitamins. At approximately 50% cell confluence, therecombinant adenoviral vector containing the bacterial β-galactosidasegene (ADV/RSV-β-gal) (Stratford-Perricaudel, et al., J. Clin. Invest.(1992)) was added at various multiplicities of infection. The transducedcells were then stained with X-gal 24 hours after transduction. Underidentical conditions, separate cell culture experiments were performedusing the ADV/RSV-TK vector followed by either PBS or GCV treatment at aconcentration of 10 ug/ml. Sixty-eight hours later, the surviving cellswere counted and compared to the PBS control plates.

In vivo experiments.

All animal experiments were performed on athymic nude (nu/nu)--mice(Harlan Sprague Dawley) using sterile technique under a laminar flowhood. Nude mice 6-10 weeks old were anesthetized by intraperitonealinjection of 0.5 ml avertin at a concentration of 20 mg/ml. Using a 100ul syringe and 26 gauge needle, a 50 ul solution containing 6×10⁶ humanHIAC-79 squamous cells in Hank's buffered saline was injected into thefloor of the mouth of nude mice. The cell suspension was slowly injectedat the depth of the mylohyoid muscle and then the needle was removedwith no apparent leakage. The animals were then maintained in standardhousing conditions for 14 days.

For the adenovirus injection, the nude mice were anesthetized as beforeand the neck skin was incised with scissors. The tumors were exposed bycareful surgical dissection, and size was measured in three dimensionsusing calipers. A microliter syringe fitted with a 25 gauge needle wasthen used to directly inject a 75 ul solution containing 1×10¹⁰adenoviral particles of either ADV/RSV-TK or ADV/RSV-βgal. Anothercontrol group received only 75 ul of phosphate buffered saline (PBS).The actual adenovirus or PBS delivery was performed with four separateneedle passes, two parallel to the long axis of the tumor and twoperpendicular to this axis. Neck incisions were closed with 4-0 silk(Ethicon). Eighteen hours after virus injections, the mice were begun onintraperitoneal ganciclovir treatments at 100 mg/kg or PBS at the samevolume for six days. The treatment mice showed no change in eating orother behavior habits during the course of the ganciclovir treatment.

The mice were sacrificed 21 days after original tumor implantation andthe lesions were carefully excised to include only the necrotic orresidual tumor mass. The tumor masses were measured with calipersimmediately after excision and then repeat measurements were made by asecond independent examiner prior to embedding for -histologicevaluation. For X-gal studies, excised tumor was embedded in O.C.T. andsnap frozen over dry ice. It was stored at -80° C. until preparation offrozen sections which were stained with X-gal (Ponder et al., PNAS(1988)). For all other histologic studies, tissue was fixed in 10%buffered formalin, embedded in paraffin, serial 3 micron sections cut,and stained with hematoxylin and eosin. Histologic sections wereexamined by a single individual (M.R.S.) who was blinded to theparticular treatments of each animal. Assessment of tumor grade,circumscription, necrosis, fibrosis, inflammatory response, and mitoticcounts were done using standard microscopic equipment. Quantitativemorphometric measurements of maximum tumor cross-sectional area, percent tumor necrosis per cross-sectional area, and mitotic figures per 10high power fields were performed using a computer-assisted image.analyzer. The system includes a Nikon Microphot-FXA microscope, Ikegami370M high resolution color camera, Sony Triniton high resolution colorvideo monitor, and a Compudyne 486 computer with Bioscan optimassoftware (Edmonds, Wash.).

Results

Efficiency of adenoviral transduction of HlaC-79 cells in vitro.

For the ADV/RSV β-gal experiments, 85% of the human squamous cancercells were transduced at a M.O.I. of 8 as demonstrated by positive blueX-gal staining, and 100% of cells were transduced at an M.O.I of 16.There was no apparent toxicity at this adenovirus concentration and thecancer cells showed no morphologic changes compared to controls. For theADV/RSV-TK experiments, transductions were performed using a range of 0(control) to 50 M.O.I. followed by either PBS or GCV treatment in themedia. Effective cancer cell killing in the GCV group was achieved at avery low M.O.I of 3 with no increased killing and no toxicity in the PBSgroup up to an M.O.I of 25 (FIG. 15). Significant cell death was seen incultures of squamous carcinoma cells transduced with adenovirus at 50 orhigher M.O.I. but not subjected to GCV treatment. These findingsindicate that ADV/RSV-TK is an efficient vector system that is effectivein killing human squamous cancer cells in vitro in combination with GCV.

Regression of human squamous cell cancers after adenoviral transduction.After original implantation of 6×10⁶ tumor cells, the mice showed slowclinical tumor growth in the floor of mouth with extension into theanterior neck over the following two weeks. There were no signs ofcachexia during this period. and all animals appeared healthy at thetime of adenovirus injections. One control group of animals wassacrificed at two weeks and histopathological examination revealed apoorly differentiated squamous cell cancer with many mitotic figures andwithout keratin formation or necrosis. There was also clinical andhistopathologic evidence of surrounding soft tissue, muscle, and bonyinvasion. A second group of control animals eventually developedcachexia and died after 35-45 days.

In the clinical experiment, there were four control groups and onecomplete treatment group: (1) PBS intratumor injection plus GCVtreatment (PBS+ G+); (2) ADV/RSV-β-gal plus PBS (β-gal+ G-); (3)ADV/RSV-β-gal plus GCV (β-gal+ G+); (4) ADV/RSV-TK plus PBS (TK+ G-):and (5) ADV/RSV-TK plus GCV (TK+ G+). The experimental animals showed nosigns of cachexia or change in eating habits during the treatment periodand all appeared clinically healthy at necropsy. The pre-treatment tumorsizes ranged from 4.36 mm² in cross sectional area with an average of13.7 mm² for all groups and 16.4 mm² for the TK+ G+ complete treatmentgroup. The wide variations in tumor size are consistent with theoriginal and only report of this cancer model (Dinesman et al.,Otolaryngol Head Neck Surg., (1990)).

The cytotoxic effects of the treatments were assessed histologically bymeasuring percent necrosis in the tumor masses using computer assistedimage analysis The PBS+ G+ and β-gal+ G- animals showed no tumornecrosis, and the TK+G- and β-gal+ G+ groups showed only focal areas ofnecrosis ranging from 0.5-5.0% of the mean cross sectional area. The TK+G+ group, however, showed substantial diffuse necrosis ranging from17-72% of the tumor mass with a mean value of 41% that was statisticallydifferent from the controls using t-Test analysis (p<0.001) (FIG. 16).

X-gal staining of sections of tumor injected with ADV/RSV-Bgaldemonstrated positive nuclear staining of 1-10% of tumor cells in adistribution consistent with the regions of needle injection. Smallislands of residual tumor could be identified in most of the completetreatment (TK+ G+) animals, however microscopic examination revealedswollen dying tumors or individually necrotic cells in these areas.There was also very low or absent mitotic activity. Three tumorspecimens showed marked fibrous obliteration with only small islands ofdying carcinoma cells within dense fibrous tissue. Only the two largesttumors in the TK+ G+ group (220 and 324 mm³ at transduction) showedsubstantial areas of viable tumor cells after treatment.

In order to objectively analyze these findings, a tumor index valueindicating overall clinical response was determined for each group usinga modification of the previously described cancer cell index calculation(Caruso et al, PNAS (1990)). The tumor index was based on morphometricmeasurements of maximum cross-sectional tumor area multiplied by themitotic activity of non-necrotic tumor mass and change in macroscopicsize. The majority of animals in the TK+ G+ group had a tumor index of"30" or less which reflects near total tumor regression with only rareviable tumor cells noted on microscopic analysis (FIG. 17). A value of"0" occurred in four TK+ G+ animals and correlates not only with anabsence of mitotic figures but also a lack of characteristic viabletumor cells upon histologic examination. The mean tumor index for thecomplete treatment group (TK+ G+) was 10-100 fold smaller and the medianvalue was 280-2400 fold smaller than values for the control groups whichdid not receive the therapeutic TK gene. When compared to the TK groupthat did not receive ganciclovir (TK+ G-), the TK+ G+ treatment grouphad mean and median tumor index values which were 6- and 55-foldsmaller. Using Mann-Whitney analysis, statistical significance wasdetermined by comparing the TK+ G+ group to each of the controls withvalues ranging from p<0.001 to p<0.02 (FIG. 16).

Local and systemic effects of adenovirus gene transfer and ganciclovirtreatment.

Two of the animals that received ADV/RSV-TK and ganciclovir treatmentwere chosen at random and samples of local tissue and distant organswere evaluated for any histological abnormalities. Surrounding muscle,soft tissue, and salivary glands in the floor of mouth and neck regionsdid not show any evidence of necrosis, dying cells, or morphologicchanges. Distant organs were also harvested at necropsy and includedsmall intestine, bladder, ovaries, spleen, heart, brain, kidney, lung,and liver. All specimens were normal on gross examination andhistological analysis revealed no metastatic tumor, necrosis, fibrosis,or other abnormal morphology. Over all, local and distant tissuesappeared normal with no apparent effects of adenovirus or ganciclovirtreatment.

These experiments are the first successful demonstration ofadenoviral-mediated gene transfer utilized for the treatment of humanhead and neck squamous cell carcinoma in a nude mouse model. Theeffectiveness of the treatment scheme is depicted by the very low M.O.Ineeded for in vitro killing and results of the two therapeutic indicesanalyzed. This human cancer cell line is highly susceptible totransduction via the adenovirus vector system as dramatic killingoccurred at an M.O.I. as low as 3. The susceptibility to adenoviraltransduction should prove advantageous by allowing lower concentrationsof ADV/RSV-TK to be delivered to tumors while maintaining successfulclinical response.

The first therapeutic index is mean tumor necrosis which was high forthe ADV/RSV-TK plus GCV group (TK+ G+), indicating a substantialcytotoxic effect of the coupled therapy. Treatment with gancicloviralone (PBS+ G+) or in conjunction with the g-gal vector (β-gal+ G+)showed no tumor necrosis, and two of the seven tumors injected with thethymidine kinase vector alone (TK+ G-) showed only microscopic regionsof focal necrosis. The remaining experimental group, β-gal vector alone(β-gal+ G-), contained microscopic focal necrosis in each tumor whichwas consistent with the sites of needle injection. Thus, the combinationof thymidine kinase gene transfer plus ganciclovir is essential indirect tumor eradication.

The second therapeutic index is based on morphometric analysis andhistologic characteristics of the tumors and has been designated thetumor index. The importance of this calculation method for tumor indexis that it provides an objective means of assessing any apparentresidual tumor as well as the overall treatment outcome, therebyeliminating possible examiner bias in interpreting tumor histology. Themajority of animals in the complete treatment group (TK+ G+) had tumorindex below "30" indicating near total tumor eradication, and fouranimals had values of "0". These findings demonstrate a definitetherapeutic effect of the thymidine kinase gene transfer and ganiclovirtreatment.

There were two high clinical response values in the TK+ G+ treatmentgroup which result from incomplete tumor killing and areas of residualviable cancer. Upon reviewing the pre-treatment gross size, the tumorvolumes for these animals were 324 and 220 mm³ compared to an averagevolume of 95 mm³ for the other tumors in the TK+ G+ group. Thesefindings suggest that a critical tumor volume exists which limits theresponse of "one time" gene transfer therapy. There were also two lowclinical response values in the TK+ G- control group, but onhistological review there was no evidence of necrosis, and the tumorcontained large numbers of mitotic figures. These low values were adirect result of the very small cross sectional area of the two tumorsand could simply be a factor of the known variable cancer growth in thismodel (Dinesman et al., Otolaryngol Head Neck Surg., (1990)). Thepossibility of an inhibitory effect on tumor growth from thymidinekinase gene transfer must be considered, however, since the tumorindices of the TK+ G- group were overall smaller than both the PBS andβ-gal adenovirus gene transfer control animals (p<0.010-0.016). Theβ-gal+ G+ and β-gal+ G- control animals also showed no statisticaldifferences in tumor response from the PBS+ G+ control group.

Athymic mice which lack T-cells (CD4+ and CD8+ lymphocytes) wereselected in these experiments for the purpose of eliminating thecellular immune response which has been implicated as a major componentof tumor regression after viral transduction (Caruso et al., PNAS(1990); Culver et al., Science (1992)). Previous studies onretroviral-mediated TK gene transfer into rat glioma tumors inimmune-competent animals have shown that infiltration of macrophages andlymphocytes occurs in these tumors (Culver et al, Science (1992)). It isbelieved that this immune reaction enhances general tumor killing afterviral transfer. In our experiments, there was no inflammatory or immunecell response in the TK+ G+ treatment group or any of control groups.Therefore, the tumoricidal response directly results from the thymidinekinase gene transfer coupled with ganciclovir administration.

The findings in our studies do support the concept of a contributionfrom what has been called "the bystander effect". In both murine andhuman sarcoma tumor models, the transfer of a toxic metabolite ofganciclovir, presumably a phosphorylated form, via gap junctions orendocytosis of apoptotic vesicles from virally transduced dying tumorcells to nearby nontransduced cells has resulted in killing of these"bystander" cells. In our experiments with human squamous cell cancer invivo, ADV/RSV-β-gal delivery resulted in only a 1-10% transduction asdetected by X-gal staining, whereas the same quantity of virus injectionwith ADV/RSV-TK showed diffuse tumor killing and necrosis in theexperimental group. Furthermore, the localized β-gal staining indicatesthat the adenovirus does not readily diffuse throughout the solid tumorto affect cancer cells distant to the site of delivery. It should alsobe noted that in vitro, similar transduction efficiencies occurred atlow multiplicity of infection for both the β-gal and TK adenovirus. Theextent of tumor killing in these large floor of mouth squamous cancersafter adenoviral transduction may occur in conjunction with some othercomponent such as the bystander effect.

Although the ADV/RSV-TK was injected directly into the tumors, someleakage did occur onto surrounding muscle, salivary gland, andsubcutaneous tissues. Microscopically, there was no necrosis or changein morphology of these surrounding normal tissues. The effects of theadenoviral-TK transduction and GCV administration are thus limited tothe actively dividing cancer cells. There was also no evidence ofsystemic damage from the treatment regimen as gross and microscopicinspection of distant organs including small intestine, bladder,ovaries, spleen, heart, brain kidney, lung, and liver revealed noinjury.

These experiments demonstrate that clinically effective in vivotreatment of human squamous cell cancer in an animal model can beachieved using adenovirus-mediated gene therapy.

EXAMPLE 5

Combination gene therapy for liver metastasis of colon carcinoma invivo.

The efficacy of combination therapy with a suicide gene and a cytokinegene to treat metastatic colon carcinoma in the liver was investigated.Tumors in the liver were generated by intrahepatic injection of a coloncarcinoma cell line (MGA 26) in syngeneic BALB mice. Recombinantadenoviral vectors containing various control and therapeutic genes wereinjected directly into the solid tumors, followed by treatment withganciclovir. While the tumors continued to grow in all animals treatedwith a control vector or a mouse interleukin-2 vector, those treatedwith a Herpes Simplex Virus/thymidine kinase vector, with or without theco-administration of the mouse interleukin-2 vector, exhibited dramaticnecrosis and regression. However, only animals treated with both vectorsdeveloped an effective systemic anti-tumoral immunity against challengesof tumorigenic doses of parental tumor cells inoculated at distantsites. The anti-tumoral immunity was associated with the presence ofMCA26 tumor specific cytolytic CD8+ T- lymphocytes. The results suggestthat combination suicide and cytokine gene therapy in vivo is a powerfulapproach for treatment of metastatic colon carcinoma in the liver.

Construction of Recombinant Adenoviral Vectors.

Construction of a replication-defective adenoviral vector containing theHerpes Simplex Virus Thymidine Kinase gene (ADV/RSV-tk) has beenreported previously (Chen, et al., PNAS (1994)). A replication-defectiveadenoviral vector containing the mouse interleukin 2 cDNA (ADV/RSV-mIL2)was similarly constructed. The peptide coding region of a mouseinterleukin 2 (mIL-2) cDNA was inserted into an expression cassetteconsisting of the RSV-LTR promoter and the polyadenylation region of thebovine growth hormone gene in an E1A-adenoviral vector backbone (Fang etal., Cancer Res. (1994)). The construct was co-transfected into 293cells with pJM17 DNA, which contains the complimenting adenoviralgenome. The recombinant adenovirus was isolated by plaque purificationfollowed by double cesium chloride gradient centrifugation. The viraltiter (pfu/ml) was determined by plaque assay.

Establishment and Treatment of Hepatic Metastasis Model of ColonCarcinoma.

Metastatic colon carcinoma was induced in the liver by intrahepaticimplantation of MCA-26 cells, which is a chemically induced, poorlydifferentiated colon carcinoma cell line derived from BALB/c mice(Corbett et al., Cancer Res. (1975)). The liver was exposed by abdominalincision and 3×10⁵ MCA-26 cells were injected at one site at the tip ofthe left lateral lobe of syngeneic mice. At day 7, the liver was exposedby abdominal incision and the tumor sizes were measured. Various titersof recombinant adenoviral vectors were injected directly into thehepatic tumors in 70 μl of 10 mM Tris-HCl, pH 7.4, 1 mM MgCl₂, 10%glycerol and 20 μg/ml of polybrene. Twelve hours after viral injection,the animals were treated intraperitoneally with ganciclovir (GCV) at 35mg/kg twice daily for 6 consecutive days.

Histopathological and Morphometric Analysis of Residual Tumors.

After various gene therapy treatments, computerized morphometricanalysis of the largest cross-sectional areas of the residual tumors wasperformed. The point counting method using a computer assisteddigitizing system with Bioquant software was chosen for morphometricanalyses as viable tumor cells were not always contiguous. Briefly, morethan 1,600 predetermined points in the region of the tumor were counted.The proportion of viable tumor cells in the nodule equalled the sum ofthe points of viable tumor cells divided by total number of points. Thefunctional area of viable tumor cells among the groups was compared byANOVA.

Distant Site Challenge in Treated Animals with Parental Tumor Cells.

One day after completion of GCV treatment, which was 2 weeks afterMCA-26 tumor cell implantation in the liver, animals in all treatmentgroups were challenged with tumorigenic doses of the parental tumorcells (MCA-26) as well as a heterologous but syngeneic breast tumor cellline (MOD). 1×10⁵ MCA-26 cells were injected subcutaneously at a singlesite on the right flank of the animals and 2×10⁶ MOD cells were injectedsubcutaneously on the contralateral site. Visible subcutaneous tumors ofsimilar sizes developed in the normal recipient animals after one week,and the presence of subcutaneous tumors in animals after various genetherapy treatments was observed for 4 weeks.

Cytotoxic T-Lymphocyte (CTh) Assay.

The CTL assay was performed according to published procedures (Coliganet al., Current Protocols in Immunology (1991)). Viable splenocytes wereisolated from various animal treatment groups at 3 days after completionof GCV treatment, which was 10 days after adenoviral vector injection.In vitro stimulation was performed in 24 well plates with 6×10⁶splenocytes and 5×10⁵ 15,000 RAD-irradiated MCA-26 cells per well, plus20 U/ml recombinant murine IL-2. ⁵¹ Cr release assays were performed bymixing various numbers of stimulated splenocytes harvested after 5 daysof culture (effector cells) with 5000 ⁵¹ Cr-labelled MCA-26 cells(target cells) in 96-well U-bottom plates. After 4 hours at 37° C. 100μl of medium was removed from each well and counted in a gamma counter.Percent cell lysis is defined as [(cpm_(exp) -cpm_(min))/(cpm_(max)-cpm_(min))]×100, where cpm_(max) represents total counts released byNP40-lysed target cells and cpm_(min) represents background countsspontaneously released by the target cells. Data represent mean specificcpm of triplicate cultures, with SEM less than 7% in all assays.

Results

Functional Characterization of Recombinant Adenoviral Vectors.

To determine whether introduction of the HSV-tk gene would render theMCA 26 colon tumor cells susceptible to killing by GCV, thereplication-defective recombinant adenoviral vector ADV/RSV-tk was usedto transduce the colon carcinoma cell line in vitro (FIG. 18). Aftertransduction with the recombinant vector and subsequent treatment withPBS, the cells were completely viable even at a multiplicity ofinfection (M.O.I.) of 12,000. After subsequent GCV treatment, however,only about 10% of the cells were viable at an MOI of 250 and there werefew surviving cells at an MOI of 1,000. The functionality of thereplication defective mIL-2 adenoviral vector (ADV/RSV-mIL2) wasillustrated by transduction of mouse B16 cells in vitro, followed bydemonstration of mIL2 activity in the conditioned media using a T-cellproliferation assay (Coligan et al., Current Protocols in Immunology(1991)). A high level of mIL-2 activity was present in the conditionedmedia of cells after transduction with mIL-2 adenoviral vector at an MOIof 500 and 1,000, but no mIL-2 activity was detected in cells transducedwith a control adenoviral vector (FIG. 19).

Regression of hepatic MCA 26 tumors in syngeneic animals aftercombination gene therapy in vivo.

An animal model for metastatic colon carcinoma in the liver wasestablished by intrahepatic implantation of 3×10⁵ MCA-26 cells. After 6days, 5×7mm² tumors were present in the liver of 60-70% of the animals.This was the tumor size selected for all subsequent gene therapyexperiments. BALB/c mice with hepatic colon carcinoma were divided intofive treatment groups: A: ADV/RSV-βgal; B: ADV/RSV-m1L2; C:ADV/RSV-βgal + ADV/RSV-mIL2; D: ADV/RSV-tk and E: ADV/RSV-tk+ADV/RSV-mIL2. The residual solid tumors in various animal treatmentgroups were measured and examined histopathologically. The animals thatwere treated with the β-gal vector had large nodules of actively growingundifferentiated carcinoma with rare and small foci of spontaneousnecrosis and many mitoses. There was compression of the adjacent liverand insignificant inflammation. The animals that were treated with them1L2 vector displayed limited subscapular necrosis, but had largenodules composed of mostly viable tumor cells with mitotic activityequal to the βgal vector treated mice. There was a moderate inflammatoryinfiltrate of lymphocytes, macrophages and eosinophils at the border ofthe tumor. Interestingly, animals treated with a combination of βgal andm1L2 vectors had more tumor necrosis with infiltration of inflammatorycells but viable tumor cells remained. The tk vector treatment group hadabundant tumor necrosis, but actively replicating neoplastic cells stillremained plentiful. All animals that were treated with the tk+mIL2vectors exhibited massive tumor necrosis surrounded by inflammatorycells. In some livers, no viable malignancy remained. The large zone ofnecrosis included a mixture of completely destroyed tumor, hemorrhageand ischemic liver damage. There were numerous macrophages, lymphocytesand granulocytes throughout. Seven of the 10 animals in the tk+mIL2combination treatment group had few residual tumor cells present and theremaining 3 animals appeared to be tumor-free.

In order to quantify the effectiveness of tk+mIL2 combination genetherapy in causing tumor regression, computerized morphometric pointcount analyses of the maximal cross sectional area of the solid tumorswere performed. The resulting tumor size measurements in the animals ofthe five treatment groups are shown in FIG. 20. All animals treated withthe βgal vector developed large tumors as expected. In the animal groupthat was treated with the mIL2 vector alone, there was a slight butinsignificant reduction in the residual tumor size. Animals treated withthe βgal and mIL2 vectors together and those treated with the tk vectoralone exhibited tumor necrosis and the residual tumor size wasapproximately 5- fold smaller than those treated with the βgal vector.In the animal group treated with both tk and mIL2 vectors, there was asignificant further reduction of the residual tumor size as compared tothe animal group treated with the tk vector alone.

Systemic anti-tumoral immunity in animals treated with tk+mIL2 vectors.

To test whether there was any antitumoral immunity in the animals thatunderwent various gene therapy treatments, protection against secondarychallenges by subcutaneous inoculation of tumorigenic doses of MCA- 26cells were performed at the conclusion of GCV administration. Allanimals in the βgal as well as the tk vector treatment groups developedhuge subcutaneous tumors at the challenge sites after 7 days. Five of 6mIL2 vector treated and 4 of 6 β-gal+mIL2 vector treated animals alsodeveloped subcutaneous tumors at the challenge site. Of the 6 tk+mIL2vector treated animals however, none developed subcutaneous tumors evenafter 4 weeks (FIG. 21). The antitumoral immunity in these animals alsoappeared to be MCA-26 cell specific, as no protection against distantsite challenge by tumorigenic doses of a heterologous but syngeneicbreast tumor cell line (MOD) was observed in the same animals (FIG. 21).

In order to evaluate critically whether tumor rejection was associatedwith sensitization of host effector cells, an in vitro cytotoxicT-lymphocyte assay was performed. Splenocytes were isolated from normalanimals and from animals in all five treatment groups three days afterconclusion of GCV treatment and cultured for five days with irradiatedMCA-26 cells. Various numbers of the stimulated effector cell populationwere incubated with chromium 51-labelled target MCA-26 cells, andpercent target cell lysis was plotted against the effector/target cellratios (FIG. 22). There was no significant CTL activity against MCA-26target cells in the splenocytes of the untreated normal mice, as well asthose animals in the first four treatment groups. There was, however, adramatic increase in MCA26 specific CTL activity in the splenocytes ofanimals treated with both the tk and mIL2 vectors (FIG. 22). Incontrast, splenocytes of tk and mIL2 treated mice failed to lyse BALB/cderived M0D breast tumor cells or YACI target cells.

To determine whether the CTL response reflected activity of CD4⁺ and/orCD8⁺ T-cells, monoclonal antibodies against either CD4 or CD8 wereincorporated as blocking reagents in the chromium-51 release assay. Themonoclonal antibody against CD8 was effective in complete abolition ofthe CTL response against MCA-26 cells, while the monoclonal antibodyagainst CD4 was ineffective (FIG. 23). These experiments provided strongevidence that CD8+ T cells from tk+mIL2 vector treated animals wereresponsible for MCA-26 specific cytotoxicity.

In this study, it was found that the direct delivery of the HSV-tk andmouse IL2 genes in recombinant adenoviral vectors to metastatic coloncarcinoma in the liver resulted in the regression of the carcinoma invivo. Neither the β-gal vector nor the mIL2 vector alone was capable ofarresting tumor growth in this model. The tk vector alone did not causesignificant necrosis, but many viable tumor cells remained. Combinationtherapy with both the tk and mIL2 vectors was not only more efficaciousin causing tumor regression with few viable tumor cells remaining, butalso resulted in the establishment of a systemic anti-tumoral immunitythat effectively protected against tumorigenic doses of the parentaltumor cells innocualted at distant sites. The specificity of thisanti-tumoral immunity against the parental tumor cells was furtherillustrated by the fact that there was not anti-tumoral immunity againsttumorigenic doses of a heterologous breast carcinoma cell lineinoculated in the same animals. Finally, it was demonstrated that theanti-tumoral immunity in these animals was associated with the presenceof MCA26 tumor specific CD8+ cytotoxic T-lymphocytes.

Interestingly, when the mIL2 vector was used in combination with 3×10⁹PFU of the β-gal vector, there was significant reduction of tumor sizesassociated with the presence of inflammatory cells and tumor necrosis.This effect appeared to be associated with the total viral dose assimilar results were also obtained in animals treated with the mIL2vector+3×10⁹ PFU of the tk vector without subsequent GCV administration.The EIA recombinant adenoviral vector is known to express low levels ofviral antigens that can solicit a cellular immune response againstvirally transduced cells in vivo, and this anti-viral immunity may beenhanced by the local expression of the interleukin-2 gene. However,there was a lack of an effective systemic CTL response to the parentaltumor cells in this treatment group and 4 of 6 animals failed to exhibitprotection against parental tumor cell challenge at a distant site.

EXAMPLE 6

Vector safety testing in non-human primates.

Toxicity tests of the ADV/RSV-tk and GCV treatment in baboons (Papiocvnocephalus).

Virus was produced having the titer of 1.6×10¹¹ particles/ml asdetermined by optical density. The vector was tested for in vitro and invivo toxicity, tk function tests, replication competence, andcontamination. Before virus injections, MRs were performed on allbaboons. Pre-op samples of serum, sperm, urine, and stool were collectedand tested wild-type adenovirus. Serum was tested for neutralizingantibodies to wild-type adenovirus. Three treatment groups wereestablished.

Group 1--Moderate dose ADV/RSV-tk, with GCV, 6-week survival.

A moderate dose of ADV/RSV-tk (1.5×10⁹ particles in 10 ul PBS with 10%glycerol) was injected in the centrum semiovale of a 16.3 year old,cycling female and a 17.5 year-old male baboon. Beginning the followingday, they began treatment with 10 mg/kg of GCV twice daily for 14 days.Samples were taken at 2 and 7 days post-injection for analysis for virusand anti-adenoviral antibodies. At 3 weeks following virus injection theanimals were MR imaged with gadolinium enhancement. At approximately 6weeks following virus injection, plasma, serum, urine, stool and spermsamples were again collected for analysis for the presence of sheddedvirus and the presence of antibodies to adenovirus, the brains wereimaged with gadolinium enhancement, and the animals were necropsied.

Gross examination of the brains showed no abnormalities. Specifically,no necrotic cavities, mass effect, hemorrhage, or subarachnoid cloudingwere seen. The brains were sampled extensively for microscopic evidenceof abnormality, and in both, small areas of macrophage infiltration andmild perivascular lymphatic cuffing were present in the centrumsemiovale of the right hemisphere. No cuffing was present beyond theright hemisphere, and no white matter edema was present. Noleptomeningitis was evident. No necrosis or viral inclusions were seen.The choroid plexus and ependyma were intact. No systemic pathology wasseen with the exception of focal hepatic lymphocytic infiltrates withoutnecrosis in one animal. The systemic examination in the other animal wasnormal.

Group 2--High dose ADV/RSV-tk, with GCV, 3-week survival.

At the FDA's explicit request two baboons were treated with a high doesof ADV/RSV-tk and GCV. ADV/RSV-tk (3×10¹⁰ particles in 200 μl PBS with10% glycerol) into the centrum semiovale of a 16 year-old, cyclingfemale and a 11 year-old male baboon. The following day the animalsbegan treatment with 10 mg/kg of GVC twice daily for 14 days via thetether system. At 2 days post-injection and at 1 week post-injectionplasma, serum, urine, stool and sperm samples were collected foranalysis for the presence of shedded virus and the presence ofantibodies to adenovirus. It was planned that if no virus was found, theanimals would be imaged with gadolinium enhancement at approximately 3weeks following virus injection and necropsied the next day. The malebaboon died 5 days after virus injection.

These animals died or were euthanized at 5 and 10 days following vectorinjection and initiation of GCV treatment. In both there was a 1.5 to1.8 cm area of liquefactive necrosis at the injection site. Thesenecrotic masses exerted mass effect. Histopathological examinationrevealed acute inflammation characterized by polymorphonuclear cells andlymphocytes admixed with eosinophilic liquefactive necrosis of thecentrum semiovale. Radiating from the necrotic mass was cerebral edemaevinced by white matter spongiosis. Intense lymphocytic perivascularcuffing was seen up to 1.5 cm away from the injection cavity in theright hemisphere. Coagulative necrosis was seen transmurally in vesselsadjacent to the injection site. Rare foci of perivascular infiltrate wasseen in the left hemisphere, brainstem, and cerebellum. Multifocalsubarachnoid lymphocytic infiltration was present predominantly over theright hemisphere, but was present to a lesser extent over the lefthemisphere and around the brainstem and cerebellum. No choroid plexus orependymal destruction was present although focal choroid plexusinflammation was seen on the right in the animal surviving for 10 days.No viral intranuclear inclusions were seen. Luxol fast blue stainedsections disclosed no loss of myelin except in the necrotic cavities.

Systemic examination disclosed congested lungs in the animal dying onday 5; and microscopic examination demonstrated eosinophilic materialfilling the alveolar spaces suggestive of neurogenic pulmonary edema. Nopulmonary inflammation was present. The animal euthanized at 10 daysshowed no systemic pathology.

Group 3--High dose ADV/RSV-tk, no GCV treatment, 3- and 5-week survival.

To differentiate between the effect of virus injection and virusinjection plus GCV administration 2 male baboons (10.5 and 11.5year-old) were injected with 3×10¹⁰ particles of ADV/RSV-tk in the samemanner as above. These two animals were not treated with GCV. Sampleswere taken and analyzed as described above. One baboon was necropsied at3 weeks after the first post-injection MR. The other baboon wasnecropsied at 6 weeks after the second MR. Tissue and fluid samples wereanalyzed as above.

The animal examined at three weeks had a 1.5 cm cystic cavity in theright centrum semiovale. No mass effect, herniation, or hemorrhage wasgrossly present. Histopathologically, the cavity was filled withmacrophages containing lipid debris. Adjacent to the cavity was mildgliosis, persistent lymphocytic inflammation, perivascular lymphocyticcuffing, and minimal white matter edema. No viral inclusions were seen,and the choroid plexus and ependyma were intact. Mild focal subarachnoidspace collections of lymphocytes were present over the right hemisphere,but not the left or around the brainstem. No systemic pathologicalalterations were present.

The animal examined at six weeks after treatment had a 1.6 cm slightlyirregular cystic cavity in the right posterior centrum semiovale. Thelining of the cavity wall was light brown, and no mass effect,herniation, or hematoma was evident. Microscopic examinationdemonstrated lipid-laden macrophages within the cavity wall, persistentlymphocytic infiltrate in the wall and around nearby blood vessels, andminimal edema and gliosis immediately adjacent to the cavity. No choroidplexus, ependymal, and or residual leptomeningeal infiltrate was seen.No systemic pathological alterations were present.

In summary, there appears to be a dose dependent neurotoxic effect ofvector with high dose treatment groups having coagulative necrosis atthe injection site which over time is cleared by macrophages to producecystic cavities. The process persists for six weeks although theinflammatory component is resolving by this point. GCV appears topotentiate the clinical toxicity of the high dose vector since bothanimals receiving high does vector plus GCV died or became ill enough torequire euthanasia. The moderate dose vector plus GCV animals exhibitedonly microscopic evidence of neurotoxicity at the injection site. Theadenoviral vector exerts dose dependent cytopathic effects via thepenton structural proteins paralleling the cytopathic effect of wildtype adenovirus. In this experiment, the fact that the high dose groupsboth with and without GC had necrosis while the moderate does animalsreceiving GVC did not, strongly suggests direct cytopathic effect ofvector rather than toxicity arising from 6k conversion of BVC to toxiccompounds. This experiment establishes the dosage threshold forcytopathology of 1.5×10⁹ particles. Vector dosage below this thresholdcoupled with BVC is toxic to dividing tumor cells while sparingnon-dividing CNS cellular constituents.

MRI Analysis of Baboon Brains Treated with Moderate and High Doses ofADV/RSV-tk.

The gross neuropathological alterations appear to be reflected in theMRI findings. Unfortunately, our high dose vector plus GCV animalssuccumbed before follow-up MRI's could be obtained. The high dose vectorwithout GCV animals both exhibited areas of high signal intensity on T2weighted images at three weeks corresponding to the cystic cavities seenat three and six weeks at necropsy. At three weeks some minimal masseffect was demonstrable by MRI. The six week MRI of the remaining animalin this group showed better delineation of the cystic cavitycorresponding to the gross pathological finding of a resolvingcircumscribed cavity. Leakage of gadolinium was seen in these animalscorresponding to the inflammatory changes around blood vessels. Themoderate dose vector plus GCV animals exhibited much less impressive MRIalterations, and no cavity formation was seen by imaging or grossinspection corresponding to the lower toxic effect of the treatmentregimen. These results indicate that MRI can be used to monitor tissueeffects of this therapy.

PCR Analvsis of Tissues from Baboons Injected with Moderate and HighDoses of ADV/RSV-tk.

Necropsy tissue (2-3 mm diameter) was used for the analysis. In cases oflarger organ specimens (brain, liver, etc.) multiple (4 to 6) tissuesamples were collected and pooled. Total DNA was isolated using SDS andproteinase K (Ausubel et al., 1987). A 1 μl aliquot of DNA from eachsample was used in the PCR reaction. The primer oligonucleotides usedwere a sense primer Adv.3205 (5'-GTGTTACTCATAGCGTAA-3') and an antisenseprimer RSV 270A (5'-GACTCCTAACCGCGACA-3'), the former primer situated inthe adenoviral and the latter in the RSV-LTR sequences and both 5' ofthe thymidine kinase gene in the recombinant plasmid pADL-1/RSV-tk usedto generate the recombinant virus. The PCR reaction was carried out for30 cycles of 30s @ 92° C., 30 s @ 50° C., and 1 m @ 72° C. The reactionmixture consisted of 50 μM of each dNTP nd 50 pM of each of the primersand 4 units of Taq polymerase in a total volume of 100 μl (Saiki, 1990).At the end of PCR a 10 μl aliquot of the product was electrophoresed ona 4% NuSieve Agarose gel. The gel was stained with ethydium bromide andvisualized under UV light. Those samples that yielded a 232 bp fragmentas seen on the gel were scored positive. The site of injection waspositive in 3 of the 4 animals that received high doses of virus. Oneanimal th at had virus sequence at the injection site also had virus inits spinal cord. The other two animals that were positive at theinjection site were negative in other areas of the CNS. No othertissues, including gonadal tissue, were positive for ADV/RSV-tksequences. The results of the analysis are listed in Table III.

                                      TABLE III                                   __________________________________________________________________________    PCR analysis of tissues from baboons injected with AVD/RSV-tk. ND = not       done.                                                                                  Mod. dose                                                                          Mod. dose                                                                          High dose                                                                          High dose                                                                          High dose                                                                          High dose                                   ORGAN    + GCV; ♀                                                                    + GCV; ♂                                                                      + GCV; ♀                                                                    + GCV; ♂                                                                      - GCV; ♂                                                                      - GCV; ♂                               __________________________________________________________________________    Injection site                                                                         -    -    +    +    +    -                                           CNS distal to site                                                                     -    -    +    -    -    -                                           Lung     ND   -    ND   -    -    -                                           Kidney   -    -    -    -    -    ND                                          Ovary/T estis                                                                          *    -    -    -    -    -                                           __________________________________________________________________________

All patents and publications mentioned in this specification areindicative of the levels of those skilled in the art to which theinvention pertains. All patents and publications are herein incorporatedby reference to the same extent as if each individual publication isspecifically and individually indicated to be incorporated by reference.

One skilled in the art will readily appreciate that the presentinvention is well adapted to carry out the objects and obtain the endsand advantages mentioned, as well as those inherent therein. Themethods, procedures, treatments, molecules, and specific compoundsdescribed herein are presently representative of preferred embodiments,are exemplary and are not intended as limitations on the scope of theinvention. Changes therein and other uses will occur to those skilled inthe art which are encompassed within the spirit of the invention and aredefined by the scope within the claims.

We claim:
 1. A method of causing regression of a solid tumor in amammal, comprising the steps of:administering an adenoviral vectordirectly into said tumor, wherein said vector is comprised of a DNAsequence encoding a suicide gene, and one or more cytokine genes,wherein said genes are operably linked to a promoter, and wherein saidtumor expresses said suicide gene and said one or more cytokine genes;and administering a prodrug in amounts sufficient to cause regression ofsaid tumor when said prodrug is converted to a toxic compound by saidsuicide gene.
 2. The method of claim 1, wherein the suicide genesequence expressed codes for a protein selected from the groupconsisting of thymidine kinase of herpes simplex virus, thymidine kinaseof varicella zoster virus and bacterial cytosine deaminase.
 3. Themethod of claim 1, wherein said one or more cytokine gene sequences isselected from the group consisting of interleukin-1, interleukin-2,interleukin-4, interleukin-6, interleukin-7, interleukin-10,interleukin-12, interferon-α, interferon-β, interferon-δ, tumor necrosisfactor-α, tumor necrosis factor-β, granulocyte-macrophage colonystimulating factor (GM-CSF) and granulocyte colony stimulating factor(G-CSF).
 4. The method of claim 1, wherein solid tumor is selected fromthe group consisting of colon, prostate, breast, lung, skin, liver,bone, pancreas, ovary, testis, bladder, kidney, brain, head and neckcancer.
 5. The method of claim 1, wherein said solid tumor is selectedfrom the group consisting of squamous cell papilloma, choroid plexuspapilloma and laryngeal papilloma.
 6. The method of claim 1, whereinsaid solid tumor is selected from the group consisting of genital warts,plantar warts, epidermodysplasia verruciformis and malignant warts. 7.The method of claim 1, wherein the suicide gene sequence to be expressedis thymidine kinase of herpes simplex virus and the prodrug isganciclovir, acyclovir, FIAU or their derivatives.
 8. The method ofclaim 1, wherein the suicide gene sequence to be expressed is bacteriacytosine deaminase and the prodrug is 5-fluorocytosine or itsderivatives.
 9. The method of claim 1, wherein the suicide gene sequenceto be expressed is varicella zoster virus thymidine kinase and theprodrug is 6-methoxypurine arabinoside or its derivatives.
 10. Themethod of claim 1, wherein said prodrug is selected from the groupconsisting of ganciclovir, acyclovir, 1-5-iodouracil FIAU,5-fluorocytosine, 6-methoxypurine arabinoside and their derivatives. 11.The method of claim 10, wherein said ganciclovir is administered in adose of about 1 mg/day/kg to about 20 mg/day/kg body weight.
 12. Themethod of claim 10, wherein said acyclovir is administered in a dose offrom about 1 mg/day/kg to about 100 mg/day/kg body weight.
 13. Themethod of claim 10, wherein s aid FIAU is administered in a dose of fromabout 1 mg/day/kg to about 50 mg/day/kg body weight.
 14. A method ofcausing regression of a solid tumor in a mammal, comprising the stepsof:introducing a first adenoviral vector and a second adenoviral vectordirectly into said solid tumor; said first adenoviral vector comprisedof a DNA sequence encoding a suicide gene operatively linked to apromoter and wherein said tumor expresses the suicide gene; and saidsecond adenoviral vector comprised of a DNA sequence encoding a cytokinegene operatively linked to a promoter and wherein said tumor expressesthe cytokine gene; and administering a prodrug in amounts sufficient tocause regression of said tumor when said prodrug is converted to a toxiccompound by said suicide gene.
 15. The method of claim 14, wherein saidpromoters are selected from the group consisting of Rous SarcomaVirus--Long Terminal Repeat, cytomegalovirus promoter, murine leukemiavirus--long terminal repeat, simian virus 40 early and late promoters,and herpes simplex virus-thymidine kinase promoter.
 16. The method ofclaim 14, wherein the suicide gene sequence expressed codes for aprotein selected from the group consisting of thymidine kinase of herpessimplex virus, thymidine kinase of varicella zoster virus and bacterialcytosine deaminase.
 17. The method of claim 14, wherein the additionaladenoviral vectors contain one or more cytokine gene sequence coding forproteins selected from the group consisting of interleukin-1,interleukin-2, interleukin-4, interleukin-6, interleukin-7,interleukin-10, interleukin-12, interferon-α, interferon-β,interferon-δ, tumor necrosis factor-α, tumor necrosis factor-β,granulocyte-macrophage colony stimulating factor (GM-CSF) andgranulocyte colony stimulating factor (G-CSF).
 18. The method of claim14, wherein solid tumor is selected from the group consisting of colon,prostate, breast, lung, skin, liver, bone, pancreas, ovary, testis,bladder, kidney, brain, head and neck cancer.
 19. The method of claim14, wherein said solid tumor is selected from the group consisting ofsquamous cell papilloma, choroid plexus papilloma and laryngealpapilloma.
 20. The method of claim 14, wherein said solid tumor isselected from the group consisting of genital warts, plantar warts,epidermodysplasia verruciformis and malignant warts.
 21. The method ofclaim 14, wherein the suicide gene sequence to be expressed is thymidinekinase of herpes simplex virus and the prodrug is ganciclovir,acyclovir, FIAU or their derivatives.
 22. The method of claim 14,wherein the suicide gene sequence to be expressed is bacterial cytosinedeaminase and the prodrug is 5-fluorocytosine or its derivatives. 23.The method of claim 14, wherein the suicide gene sequence to beexpressed is varicella zoster virus thymidine kinase and the prodrug is6-methoxypurine arabinoside or its derivatives.
 24. The method of claim14, wherein said tumor is liver cancer and said promoter is selectedfrom the group consisting of an albumin promoter, an alpha-fetoproteinpromoter, an α-antitrypsin promoter and a phosphoenol pyruvatecarboxykinase promoter.
 25. The method of claim 14, wherein said tumoris colon cancer and said promoter is a carbonic anhydrase I promoter ora carcinoembryogenic antigen promoter.
 26. The method of claim 14,wherein said tumor is ovarian cancer and said promoter is selected fromthe group consisting of an estrogen promoter, an aromatase cytochromeP450 promoter, a cholesterol side chain cleavage P450 and a 17alpha-hydroxylase P450 promoter.
 27. The method of claim 14, whereinsaid tumor is prostate cancer and said promoter is selected from thegroup consisting of a prostate specific antigen promoter, a gp91-phoxgene promoter and a prostate-specific kallikrein promoter.
 28. Themethod of claim 14, wherein said tumor is breast cancer and the promoteris selected from the group consisting of an erb-B₂ promoter, an erb-B₃promoter, β-casein promoter, WAB (whey acidic protein) promoter andβ-lacto-globulin promoter.
 29. The method of claim 14, wherein saidtumor is lung cancer and the promoter is selected from the groupconsisting of a surfactant promoter, a carcinoembryonic antigen promoterand Uroglobin promoter.
 30. The method of claim 14, wherein said tumoris skin cancer and the promoter is selected from the group consisting ofa human keratin 1 promoter, human keratin 6 promoter and loicrinpromoter.
 31. The method of claim 14, wherein said tumor is brain cancerand the promoter is selected from the group consisting of a glialfibrillary acidic protein promoter, a mature astrocyte specific proteinmyelin promoter and a tyrosine hydroxylase promoter.
 32. The method ofclaim 14, wherein said tumor is pancreatic cancer and the promoter isselected from the group consisting of a villin promoter, a glucagonpromoter, an islet amyloid polypeptide (amylin) promoter and insulinpromoter.
 33. The method of claim 14, wherein said tumor is thyroidcancer and the promoter is selected from the group consisting of athyroglobulin promoter and a calcitonin promoter.
 34. The method ofclaim 14, wherein said tumor is bone cancer and the promoter is selectedfrom the group consisting of an Alpha 1 (I) collagen promoter,osteocalcin promoter and sialoglycoprotein promoter.
 35. The method ofclaim 14, wherein said tumor is kidney cancer and the promoter isselected from the group consisting of a renin promoter, aliver/bone/kidney alkaline phosphatase promoter and erythropoietin (epo)promoter.
 36. The method of claim 14, wherein said prodrug is selectedfrom the group consisting of ganciclovir, acyclovir, 1-5-iodouracilFIAU, 5-fluorocytosine, 6-methoxypurine arabinoside and theirderivatives.
 37. The method of claim 36, wherein said ganciclovir isadministered in a dose of about 1 mg/day/kg to about 20 mg/day/kg bodyweight.
 38. The method of claim 36, wherein said acyclovir isadministered in a dose of from about 1 mg/day/kg to about 100 mg/day/kgbody weight.
 39. The method of claim 36, wherein said FIAU isadministered in a dose of from about 1 mg/day/kg to about 50 mg/day/kgbody weight.
 40. A method of causing regression of a solid tumor in amammal, comprising the steps of:administering an adenoviral vectordirectly into said tumor, wherein said vector or vectors are comprisedof a DNA sequence encoding a suicide gene selected from the groupconsisting of genes encoding HSV-tk or VZV-tk, and a gene encoding IL-2,wherein said genes are operably linked to a promoter, and wherein saidtumor expresses said suicide gene and said IL-2 gene; and administeringa prodrug in amounts sufficient to cause regression of said tumor whensaid prodrug is converted to a toxic compound by said suicide gene. 41.The method of claim 40 wherein said suicide gene encodes HSV-tk.
 42. Themethod of claim 40 wherein said suicide gene encodes VZV-tk.
 43. Amethod of causing regression of a solid tumor in a mammal, comprisingthe steps of:introducing a first adenoviral vector and a secondadenoviral vector directly into said solid tumor; said first adenoviralvector comprised of a DNA sequence encoding a suicide gene, selectedfrom the group consisting of genes encoding HSV-tk and VZV-tk,operatively linked to a promoter and wherein said tumor expresses thesuicide gene; and said second adenoviral vector comprised of a DNAsequence encoding a cytokine gene encoding IL-2 operatively linked to apromoter and wherein said tumor expresses the cytokine gene; andadministering a prodrug in amounts sufficient to cause regression ofsaid tumor when said prodrug is converted to a toxic compound by saidsuicide gene.
 44. The method of claim 43 wherein said suicide geneencodes HSV-tk.
 45. The method of claim 43 wherein said suicide geneencodes VZV-tk.